Primer on tumor immunology and cancer immunotherapy

35Citations
Citations of this article
162Readers
Mendeley users who have this article in their library.

Abstract

Individualized cancer therapy is a central goal of cancer biologists. Immunotherapy is a rational means to this end-because the immune system can recognize a virtually limitless number of antigens secondary to the biology of genetic recombination in B and T lymphocytes. The immune system is exquisitely structured to distinguish self from non-self, as demonstrated by anti-microbial immune responses. Moreover the immune system has the potential to recognize self from "altered-self", which is the case for cancer. However, the immune system has mechanisms in place to inhibit self-reactive responses, many of which are usurped by evolving tumors. Understanding the interaction of cancer with the immune system provides insights into mechanisms that can be exploited to disinhibit anti-tumor immune responses. Here, we summarize the 2012 SITC Primer, reviewing past, present, and emerging immunotherapeutic approaches for the treatment of cancer-including targeting innate versus adaptive immune components; targeting and/or utilizing dendritic cells and T cells; the role of the tumor microenvironment; and immune checkpoint blockade.

Cite

CITATION STYLE

APA

Harris, T. J., & Drake, C. G. (2013). Primer on tumor immunology and cancer immunotherapy. Journal for ImmunoTherapy of Cancer. BioMed Central Ltd. https://doi.org/10.1186/2051-1426-1-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free